Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00240344
First received: October 16, 2005
Last updated: August 29, 2011
Last verified: August 2011
  Purpose

The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.


Condition Phase
Hypercholesterolemia
Phase 4

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: REALISTIC: Protocol for an Observational Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New EAS LDL-C Target Goal

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 2650
Study Start Date: September 2004
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care

Criteria

Inclusion Criteria:

  • High risk patients
  • High doses of other statins
  • LDL-C known, starts with Crestor 10 mg
  • Permission to use patient data by AstraZeneca (AZ)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00240344

  Hide Study Locations
Locations
Netherlands
Research Site
Alkmaar, Netherlands
Research Site
Almelo, Netherlands
Research Site
Alphen Aan Den Rijn, Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Apeldoorn, Netherlands
Research Site
Assen, Netherlands
Research Site
Bergen Op Zoom, Netherlands
Research Site
Beverwijk, Netherlands
Research Site
Bilthoven, Netherlands
Research Site
Blaricum, Netherlands
Research Site
Boxmeer, Netherlands
Research Site
Breda, Netherlands
Research Site
Brunssum, Netherlands
Research Site
Capelle Aan Den Ijssel, Netherlands
Research Site
Delft, Netherlands
Research Site
Delfzijl, Netherlands
Research Site
Den Helder, Netherlands
Research Site
Dirksland, Netherlands
Research Site
Doetinchem, Netherlands
Research Site
Dokkum, Netherlands
Research Site
Dordrecht, Netherlands
Research Site
Drachten, Netherlands
Research Site
Ede Gld, Netherlands
Research Site
Eindhoven, Netherlands
Research Site
Emmen, Netherlands
Research Site
Enschede, Netherlands
Research Site
Etten-leur, Netherlands
Research Site
Geldrop, Netherlands
Research Site
Gouda, Netherlands
Research Site
Groningen, Netherlands
Research Site
Haarlem, Netherlands
Research Site
Hardenberg, Netherlands
Research Site
Heerenveen, Netherlands
Research Site
Heerlen, Netherlands
Research Site
Helmond, Netherlands
Research Site
Hengelo Ov, Netherlands
Research Site
Hoofddorp, Netherlands
Research Site
Hoogeveen, Netherlands
Research Site
Hoorn Nh, Netherlands
Research Site
Ijmuiden, Netherlands
Research Site
Landsmeer, Netherlands
Research Site
Leiden, Netherlands
Research Site
Lelystad, Netherlands
Research Site
Maastricht, Netherlands
Research Site
Meppel, Netherlands
Research Site
Oosterhout Nb, Netherlands
Research Site
OSS, Netherlands
Research Site
Purmerend, Netherlands
Research Site
Roermond, Netherlands
Research Site
Roosendaal, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
S-gravenhage, Netherlands
Research Site
S-hertogenbosch, Netherlands
Research Site
Schiedam, Netherlands
Research Site
Sneek, Netherlands
Research Site
Spijkenisse, Netherlands
Research Site
Stadskanaal, Netherlands
Research Site
Terneuzen, Netherlands
Research Site
Tiel, Netherlands
Research Site
Tilburg, Netherlands
Research Site
Utrecht, Netherlands
Research Site
Veghel, Netherlands
Research Site
Veldhoven, Netherlands
Research Site
Venlo, Netherlands
Research Site
Vlaardingen, Netherlands
Research Site
Vlissingen, Netherlands
Research Site
Waalwijk, Netherlands
Research Site
Weert, Netherlands
Research Site
Winschoten, Netherlands
Research Site
Winterswijk, Netherlands
Research Site
Zaandam, Netherlands
Research Site
Zevenaar, Netherlands
Research Site
Zoetermeer, Netherlands
Research Site
Zutphen, Netherlands
Research Site
Zwolle, Netherlands
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Netherlands Medical Director, MD AstraZeneca
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00240344     History of Changes
Other Study ID Numbers: NL401142, REALISTIC
Study First Received: October 16, 2005
Last Updated: August 29, 2011
Health Authority: European Union: European Medicines Agency

Keywords provided by AstraZeneca:
High risk patients
Crestor
Rosuvastatin
LDL cholesterol
observational

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 20, 2014